Chapter 023

Antihypertensive Drugs

Frank J. Dowd and William B. Jeffries

GENERAL REFERENCES

  1. Bader M: Tissue renin-angiotensin-aldosterone systems: targets for pharmacological therapy, Annu Rev Pharmacol Toxicolol 50:439–465, 2010. PUBMED Abstract
  2. Calhoun DA: Hyperaldosteronism as a common cause of resistant hypertension, Annu Rev Med 64:233–247, 2013. PUBMED Abstract
  3. Drugs for hypertension, Med Letter(141)31–39, 2014.
  4. Feldman RD, Hussain Y, Kuyper LM, et al.: Intraclass differences among antihypertensive drugs, Annu Rev Pharmacol Toxicol 55:333–352, 2015. PUBMED Abstract
  5. Frumkin LR: The pharmacological treatment of pulmonary hypertension, Pharmacol Rev 64:583–620, 2012. PUBMED Abstract
  6. Ghamami N: Time course for blood pressure lowering of dihydropyridine calcium channel blockers, Cochrane Database Syst Rev 8, Aug. 31, 2014. PUBMED Abstract
  7. James PA, Oparil S, Carter BL, et al.: Evidenced-based guidelines for the management of high blood pressure in adults, Report from the panel members appointed to the Eight Joint National Committee (JNC 8), J Am Med Assoc 311:507–520, 2014. PUBMED Abstract
  8. Levine DA, Lewis CE, Williams OD, et al.: Geographic and demographic variability in 20-year hypertension incidence, the CARDIA study, Hypertension 57:39–47, 2011. PUBMED Abstract
  9. Morisco C, Trimarco B: Angiotensin converting enzyme inhibitors and AT1 antagonists for treatment of hypertension. In ACEi and ARBS in hypertension and Heart Failure, Current Cardiovascular Therapy, 5. New York, 2015, Springer, pp 1–39.
  10. Rik HG, Engberink O, Frenkel WJ, et al.: Effects of thiazide-type and thiazide-like diuretics on cardiovascular events and mortality: systematic review and meta-analysis, Hypertension 65:1033–1040, 2015. PUBMED Abstract